A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

• Status: Recruiting
• Trial end date: 2025-11-25
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)

• Have either

• no T2D with an HbA1c < 6.5% or

• have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.

• Have been diagnosed with chronic kidney disease (CKD).

Exclusion Criteria:

• Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening.

• Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin

• Have a prior or planned surgical treatment for obesity

• Have Type 1 Diabetes (T1D)

• Have acute or chronic hepatitis

• Have a history of malignant disease within 5 years before screening.